Last year at the World Conference on Lung Cancer, Bristol Myers Squibb made waves in mesothelioma with data showing its Opdivo – Yervoy duo could slash the risk of death in previously untreated patients. This year, it grabbed the spotlight with another survival win in the tough-to-treat disease.
Saturday, solo Opdivo became the first med to show in a randomized phase 3 trial that it could extend the lives of previously treated mesothelioma patients, cutting their risk of death by 28% against placebo. Those taking Opdivo lived for a median 9.2 months, versus 6.6 months for those in the placebo arm.
Opdivo also staved off disease worsening, slashing the risk of progression or death by 39%. At the one-year mark, 14.5% of Opdivo patients hadn’t seen their cancer worsen, and only 4.9% of placebo patients could say the same.
The results follow on the heels of Opdivo’s performance in first-line mesothelioma from the last WCLC meeting in August. In tandem with Yervoy, BMS’ checkpoint star pared down patients’ risk of death by 26% against chemo, a showing that ultimately earned the pair an FDA green light.
Asbestos-Mesothelioma Case Evaluation
Free. Confidential. No Obligation.